Nanofacile

Developing RNA therapies is currently a slow, expensive, and expertise-dependent process, creating significant barriers to bringing new treatments to market. Nanofacile's Nanomedicine in a Box platform addresses this by offering a first-in-class, standalone kit that drastically accelerates RNA therapeutic development. This technology allows for the rapid, parallel screening of multiple lipid nanoparticle (LNP)-encapsulated RNA therapies, reducing preclinical development time by at least 10-fold without large capital expenditures. The platform also includes an AI-assisted formulation companion to optimize LNP compositions and ensure reproducibility, ultimately simplifying and speeding up the RNA formulation process.

mRNA therapies were propelled by the success of vaccines against COVID-19. Now, the same technology can be used against cancer, metabolic diseases and in gene therapies. However, developing RNA therapies is slow, expensive and expertise-dependent. Biotech innovators, academia and CROs face two options. They either pay up to $40K for RNA encapsulation to a 3rd party that might take a few weeks to get one single formulation with low probability of success, or risk up to $300K in equipment plus salaries and months of development, with uncertain results. This problem creates barriers that hinder new therapies to come to market, and discourage innovation. Conventional high-throughput technologies currently available on the market suffer from major limitations, including significant inter-sample variability caused by extended processing times, high CapEx, and no formulation support. Moreover, existing assembler platforms are unable to generate particles that are immediately ready for downstream analyses.

Nanofacile's Nanomedicine in a Box is a first-in-class technology platform kit that accelerates RNA therapeutic development. It features a standalone, sterile, single-use device compatible with standard laboratory equipment, enabling parallel screening of multiple lipid nanoparticle (LNP)-encapsulated RNA therapies ready for downstream in vitro and in vivo testing. This dramatically reduces preclinical development time by at least 10-fold, without the need for capital expenditures or specialized equipment. The kit includes validated reagents and lipid formulations designed to increase the success rate. Our proprietary AI-assisted formulation companion (prototyping) enhances the R&D process by optimizing LNP compositions, automating data analysis, and ensuring reproducibility across batches. The system also delivers real-time feedback on key parameters such as LNP size, encapsulation efficiency, and transfection performance, while supporting regulatory compliance through robust, traceable data management.